Rigel Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved by the...

PR NewswireApr 11 04:30

Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients With Mutant IDH1 AML in Leukemia & Lymphoma

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a peer-reviewed publication in Leukemia & Lymphoma on data from an analysis of the Phase 2 ...

PR NewswireApr 4 20:05

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

Dow JonesMar 12 20:05

Rigel Pharmaceuticals Inc (RIGL) Reports Growth in 2023 Sales, Despite Net Loss for the Year

Yahoo FinanceMar 8 02:50

Rigel Pharmaceuticals Is Maintained at Buy by Citigroup

Rigel Pharmaceuticals Is Maintained at Buy by Citigroup

Dow JonesMar 7 22:41

Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $4

Citigroup analyst Yigal Nochomovitz maintains Rigel Pharmaceuticals with a Buy and raises the price target from $3 to $4.

Analyst UpgradesMar 7 22:30